Skip to main content
SpringerLink
Log in

Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Xue SL, Wu DP, Sun AN, Tang XW (2008) CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. Am J Hematol 83(2):167–170. https://doi.org/10.1002/ajh.21066

    Article  CAS  PubMed  Google Scholar 

  2. Gu LF, Zhang WG, Wang FX, Cao XM, Chen YX, He AL, Liu J, Ma XR (2011) Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 137(6):997–1003. https://doi.org/10.1007/s00432-010-0947-z

    Article  CAS  PubMed  Google Scholar 

  3. Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Cante-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P (2014) ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124(25):3738–3747. https://doi.org/10.1182/blood-2014-05-574566

    Article  CAS  PubMed  Google Scholar 

  4. Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A (2014) Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer discovery 4(9):1074–1087. https://doi.org/10.1158/2159-8290.CD-14-0353

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K (2019) The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. Leukemia 33(2):319–332. https://doi.org/10.1038/s41375-018-0176-z

    Article  CAS  PubMed  Google Scholar 

  6. Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagykary N, Bradner JE, Lan Zhang G, Look AT, Feng H (2014) BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia 28(5):1145–1148. https://doi.org/10.1038/leu.2013.377

    Article  CAS  PubMed  Google Scholar 

  7. Li Z, He S, Look AT (2019) The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. Leukemia 33(1):262–266. https://doi.org/10.1038/s41375-018-0201-2

    Article  PubMed  Google Scholar 

  8. Peirs S, Frismantas V, Matthijssens F, Van Loocke W, Pieters T, Vandamme N, Lintermans B, Dobay MP, Berx G, Poppe B, Goossens S, Bornhauser BC, Bourquin JP, Van Vlierberghe P (2017) Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia 31(10):2037–2047. https://doi.org/10.1038/leu.2017.10

    Article  CAS  PubMed  Google Scholar 

  9. Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD (2018) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32(3):788–800. https://doi.org/10.1038/leu.2017.276

    Article  CAS  PubMed  Google Scholar 

  10. Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN (2018) Venetoclax in combination with Decitabine for relapsed T-cell acute lymphoblastic leukemia after allogeneic hematopoietic cell transplant. Case reports in hematology 2018:6092646. https://doi.org/10.1155/2018/6092646

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thanked all members of the Zhejiang University Institute of Hematology for technical support to diagnosis. We also thanked Yile Zhou for providing advices to improve the English language.

Funding

This study was funded by the National Natural Science Foundation of China (81670124, 81800199) and the General Research Foundation of Zhejiang Provincial Department of Education (Y201738138).

Author information

Authors and Affiliations

  1. Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, 310003, Zhejiang, China

    Xiang Zhang, Jianhu Li, Jie Jin & Wenjuan Yu

  2. Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China

    Xiang Zhang, Jie Jin & Wenjuan Yu

  3. Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, Hangzhou, Zhejiang, China

    Xiang Zhang, Jie Jin & Wenjuan Yu

  4. Bone marrow morphology laboratory, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China

    Jianhu Li

Authors
  1. Xiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianhu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jie Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenjuan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

X. Z., J.-H. L., J.J., and W.-J. Y. collected and analyzed the clinical data and made the summary. X. Z. designed this study and wrote this manuscript. W.-J. Y. revised this manuscript. All authors approved the manuscript.

Corresponding author

Correspondence to Wenjuan Yu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Li, J., Jin, J. et al. Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen. Ann Hematol 99, 395–397 (2020). https://doi.org/10.1007/s00277-019-03902-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03902-9

Search

Navigation